Announcements Trials
Browse Landscape

Phase

Phase 3 2

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 2

Conditions

Breast Neoplasms 376Neoplasm Metastasis 21Neoplasms 11Advanced Breast Cancer 10Carcinoma, Intraductal, Noninfiltrating 8Triple Negative Breast Neoplasms 7Osteoporosis 7Carcinoma, Ductal, Breast 7Breast Neoplasms, Male 7Breast Diseases 7Breast Carcinoma In Situ 6Carcinoma, Lobular 5Prostatic Neoplasms 4Hereditary Sensory and Autonomic Neuropathies 4Breast Cancer Metastatic 4Arthralgia 4Recurrence 3Ovarian Neoplasms 3Neoplasms, Hormone-Dependent 3Squamous Cell Carcinoma of Head and Neck 2Pain 2Obesity 2Neoplasms by Site 2Multiple Endocrine Neoplasia Type 1 2Infertility 2Head and Neck Neoplasms 2HR+/HER2- Breast Cancer 2HR Positive HER2 Negative Advanced Breast Cancer 2Estrogen Receptor-positive Breast Cancer 2Endometrial Neoplasms 2

Interventions

Zoledronic Acid 3Risedronic Acid 3Letrozole 2Exercise Movement Techniques 1Denosumab 1Calcium 1Aromatase Inhibitors 1Anastrozole 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Bone Diseases, Metabolic × Letrozole × Breast × Clear all
NCT00050011 2014-03-21

Zoledronic Acid - Letrozole Adjuvant Synergy Trial (ZFAST) - Cancer Treatment Related Bone Loss in Postmenopausal Women With Estrogen Receptor Positive and/or Progesterone Receptor Positive Breast Cancer Receiving Adjuvant Hormonal Therapy

Novartis

Phase 3 Completed
602 enrolled 13 charts
Breast

Bone Diseases, Metabolic, Breast Neoplasms, Osteoporosis

NCT00171340 2012-04-16

Zoledronic Acid in the Prevention of Cancer Treatment Related Bone Loss in Postmenopausal Women Receiving Letrozole for Breast Cancer.

Novartis

Phase 3 Completed
1,065 enrolled 10 charts
Breast

Bone Diseases, Metabolic, Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡